0M26 Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$26.64 |
| 52 Week High | US$26.64 |
| 52 Week Low | US$13.96 |
| Beta | 0.93 |
| 11 Month Change | 11.00% |
| 3 Month Change | n/a |
| 1 Year Change | 65.70% |
| 33 Year Change | -20.20% |
| 5 Year Change | n/a |
| Change since IPO | -20.22% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0M26 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 3.3% | -7.6% | -1.2% |
| 1Y | 65.7% | -28.6% | 4.4% |
Return vs Industry: 0M26 exceeded the UK Biotechs industry which returned -27.1% over the past year.
Return vs Market: 0M26 exceeded the UK Market which returned 5.4% over the past year.
Price Volatility
| 0M26 volatility | |
|---|---|
| 0M26 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.7% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0M26 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0M26's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| 0M26 fundamental statistics | |
|---|---|
| Market cap | US$319.01m |
| Earnings (TTM) | -US$45.08m |
| Revenue (TTM) | US$5.81m |
54.9x
P/S Ratio-7.1x
P/E RatioIs 0M26 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0M26 income statement (TTM) | |
|---|---|
| Revenue | US$5.81m |
| Cost of Revenue | US$122.00k |
| Gross Profit | US$5.69m |
| Other Expenses | US$50.77m |
| Earnings | -US$45.08m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.87 |
| Gross Margin | 97.90% |
| Net Profit Margin | -775.86% |
| Debt/Equity Ratio | 146.6% |
How did 0M26 perform over the long term?
See historical performance and comparison